These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 33882657)

  • 1. [New Hopes in Vaccine Technology: mRNA Vaccines].
    Yılmaz E
    Mikrobiyol Bul; 2021 Apr; 55(2):265-284. PubMed ID: 33882657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancing mRNA technologies for therapies and vaccines: An African context.
    Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K
    Front Immunol; 2022; 13():1018961. PubMed ID: 36353641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.
    Maruggi G; Zhang C; Li J; Ulmer JB; Yu D
    Mol Ther; 2019 Apr; 27(4):757-772. PubMed ID: 30803823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action.
    Maruggi G; Ulmer JB; Rappuoli R; Yu D
    Curr Top Microbiol Immunol; 2022; 440():31-70. PubMed ID: 33861374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials.
    Sobhani N; Scaggiante B; Morris R; Chai D; Catalano M; Tardiel-Cyril DR; Neeli P; Roviello G; Mondani G; Li Y
    Cancer Treat Rev; 2022 Sep; 109():102429. PubMed ID: 35759856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and Delivery Technologies for mRNA Vaccines.
    Zeng C; Zhang C; Walker PG; Dong Y
    Curr Top Microbiol Immunol; 2022; 440():71-110. PubMed ID: 32483657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA vaccines - a new era in vaccinology.
    Pardi N; Hogan MJ; Porter FW; Weissman D
    Nat Rev Drug Discov; 2018 Apr; 17(4):261-279. PubMed ID: 29326426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses.
    Vogel AB; Lambert L; Kinnear E; Busse D; Erbar S; Reuter KC; Wicke L; Perkovic M; Beissert T; Haas H; Reece ST; Sahin U; Tregoning JS
    Mol Ther; 2018 Feb; 26(2):446-455. PubMed ID: 29275847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical progress and challenges of mRNA vaccines.
    Yu MZ; Wang NN; Zhu JQ; Lin YX
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1894. PubMed ID: 37096256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Developments and Challenges of mRNA Vaccines.
    Chen J; Chen J; Xu Q
    Annu Rev Biomed Eng; 2022 Jun; 24():85-109. PubMed ID: 35231177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-amplifying mRNA vaccines.
    Brito LA; Kommareddy S; Maione D; Uematsu Y; Giovani C; Berlanda Scorza F; Otten GR; Yu D; Mandl CW; Mason PW; Dormitzer PR; Ulmer JB; Geall AJ
    Adv Genet; 2015; 89():179-233. PubMed ID: 25620012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in RNA Vaccines for Preventive Indications: A Case Study of A Vaccine Against Rabies.
    Armbruster N; Jasny E; Petsch B
    Vaccines (Basel); 2019 Sep; 7(4):. PubMed ID: 31569785
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic mRNA Engineering from Head to Tail.
    Jia L; Qian SB
    Acc Chem Res; 2021 Dec; 54(23):4272-4282. PubMed ID: 34756012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Building a Better Silver Bullet: Current Status and Perspectives of Non-Viral Vectors for mRNA Vaccines.
    Gu J; Xu Z; Liu Q; Tang S; Zhang W; Xie S; Chen X; Chen J; Yong KT; Yang C; Xu G
    Adv Healthc Mater; 2024 Jan; 13(3):e2302409. PubMed ID: 37964681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of RNA-based treatments in the field of cancer immunotherapy.
    Chehelgerdi M; Chehelgerdi M
    Mol Cancer; 2023 Jul; 22(1):106. PubMed ID: 37420174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination.
    Tombácz I; Weissman D; Pardi N
    Methods Mol Biol; 2021; 2197():13-31. PubMed ID: 32827130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines.
    Wei J; Hui AM
    Cancer Treat Rev; 2022 Jun; 107():102405. PubMed ID: 35576777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines.
    Guevara ML; Persano S; Persano F
    Curr Pharm Des; 2019; 25(13):1443-1454. PubMed ID: 31258071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future.
    Perenkov AD; Sergeeva AD; Vedunova MV; Krysko DV
    Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37897003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.
    Deering RP; Kommareddy S; Ulmer JB; Brito LA; Geall AJ
    Expert Opin Drug Deliv; 2014 Jun; 11(6):885-99. PubMed ID: 24665982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.